- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07945665
Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions
A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing
This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Wang Jiazheng
- Telefonní číslo: +8615800536923
- E-mail: wangjiazheng@wolwobiotech.com
Studijní místa
-
-
-
Beijing, Čína, 100730
- Beijing Tongren Hospital, Capital Medical University
-
Kontakt:
- Zhang Luo
- Telefonní číslo: +861065141136
- E-mail: dr.luozhang@139.com
-
-
Hubei
-
Wuhan, Hubei, Čína, 430030
- Tongji Hospital, Tongji Medical College of Hust
-
Kontakt:
- Zhu Rongfei
- Telefonní číslo: +862783662912
- E-mail: Zrf13092@163.com
-
-
Shanxi
-
Taiyuan, Shanxi, Čína, 030032
- Shanxi Bethune Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female participants aged 18-60 years, inclusive.
- Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
- Participants who are able to understand the study and voluntarily provide written informed consent.
Exclusion Criteria:
- History of needle-related syncope or vasovagal reactions to the sight of blood.
- Pregnant or breastfeeding women.
- History of malignant tumors.
- Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
- Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
- Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
- Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
- Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
- Systemic use of immunosuppressants within 14 days before SPT.
- Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
- Treatment with dupilumab or similar agents within 3 months before SPT.
- Treatment with omalizumab or similar agents within 5 months before SPT.
- Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
- Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
- Positive skin scratch test for dermographism during screening.
- Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Skin Prick Test Group
All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session. |
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Ragweed Pollen (3,500 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (19,500 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (19,500 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Sensitivity: Dog Dander (39,000 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
|
Specificity: Dog Dander (39,000 DU/mL)
Časové okno: 15-20 minutes after skin prick testing (Day 1).
|
Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met. |
15-20 minutes after skin prick testing (Day 1).
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Adverse Events
Časové okno: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable. |
From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
|
|
Changes in Vital Signs from Baseline
Časové okno: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
|
|
Changes in Physical Examination Findings from Baseline
Časové okno: At screening and on Day 2 of the study or at early termination.
|
Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Hematology Parameters from Baseline
Časové okno: At screening and on Day 2 of the study or at early termination.
|
Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
|
Changes in Urinalysis Parameters from Baseline
Časové okno: At screening and on Day 2 of the study or at early termination.
|
Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed. |
At screening and on Day 2 of the study or at early termination.
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- WOLWO-D1-0III32-1
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .